Histogen, Inc. (HSTO)
| Market Cap | 33.80M |
| Revenue (ttm) | 1.41M |
| Net Income (ttm) | -14.73M |
| Shares Out | 37.20M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331,070 |
| Open | 0.800 |
| Previous Close | 0.783 |
| Day's Range | 0.770 - 0.809 |
| 52-Week Range | 0.743 - 2.410 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 2.70 (+241.4%) |
| Est. Earnings Date | Nov 10, 2021 |
About HSTO
Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of ...
Financial Performance
In 2020, Histogen's revenue was $2.06 million, a decrease of -82.02% compared to the previous year's $11.45 million. Losses were -$18.77 million, 532.8% more than in 2019.
Financial StatementsNews
Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September
Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen Shares Additional Emricasan Data From COVID-19 Study
Histogen Inc (NASDAQ: HSTO) and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients. As previously reported, emricasan...
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19...
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptoma...
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events
Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
Histogen Reports First Quarter 2021 Earnings and Provides Business Update
Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises
Histogen Appoints Rochelle Fuhrmann to Board of Directors
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients
Topline Results Expected in the Second Quarter of 2021 Topline Results Expected in the Second Quarter of 2021
Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage R...
Trial Initiation Anticipated in Second Quarter 2021
Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises
Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...
Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...
DLA Piper advises Histogen in its US$14 million upsized public offering
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that...
Histogen Announces Closing of $14.0 Million Upsized Public Offering
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...
Histogen Announces Pricing of $14.0 Million Upsized Public Offering
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publi...
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the ...
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. w...
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockho...